KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Acquisitions (2018 - 2021)

Historic Acquisitions for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q4 2021 value amounting to $72.7 million.

  • Amneal Pharmaceuticals' Acquisitions changed N/A to $72.7 million in Q4 2021 from the same period last year, while for Dec 2022 it was $72.7 million, marking a year-over-year decrease of 5037.98%. This contributed to the annual value of $84.7 million for FY2022, which is 4219.17% down from last year.
  • According to the latest figures from Q4 2021, Amneal Pharmaceuticals' Acquisitions is $72.7 million.
  • Amneal Pharmaceuticals' Acquisitions' 5-year high stood at $253.6 million during Q1 2020, with a 5-year trough of -$2.6 million in Q3 2020.
  • Moreover, its 3-year median value for Acquisitions was $38.0 million (2018), whereas its average is $66.9 million.
  • The largest annual percentage gain for Amneal Pharmaceuticals' Acquisitions in the last 5 years was 1958746.67% (2021), contrasted with its biggest fall of 1958746.67% (2021).
  • Quarter analysis of 3 years shows Amneal Pharmaceuticals' Acquisitions stood at $3.3 million in 2018, then plummeted by 179.76% to -$2.6 million in 2020, then surged by 2854.36% to $72.7 million in 2021.
  • Its last three reported values are $72.7 million in Q4 2021, $73.8 million for Q2 2021, and -$2.6 million during Q3 2020.